2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2578

Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2654

Exposure to Air Pollution and the Onset and Progression of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2142

Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2519

Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2049

Expression and Function of a Novel Citrullinated Form of Interleukin 6 in Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2029

Extended Phenotypic Immunome Characterization (EPIC): A Web-Based Immune Reference Atlas

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2753

Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2366

Facilitating Shared Decision Making in Psoriatic Arthritis: Factors Influencing Patient Preference for Treatment Mode of Administration

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2285

Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

9:00AM-11:00AM: Abstract Number: 2717

Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized–Controlled Trials

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2442

Familial Mediterranean Fever Associated Infertility and Underlying Factors with Fertility

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2552

Fatigue in Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Early Improvement Is Associated with Week 24 Outcomes in Acr 20, 50, and Health-Related Quality of Life

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2743

Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2212

Feasibility and Performance of HR-pQCT-Derived Joint Space Width Measurement As Outcome Parameter in Arthropathic Disease – Lessons from Hemochromatosis Arthropathy

Imaging of Rheumatic Diseases Poster III: Other Modalities

9:00AM-11:00AM: Abstract Number: 2493

Features of Disease Severity Associated with Patient Satisfaction with Biologic Treatment: Results from the Abatacept Best Care Real-World Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].